Atypical MOLes and Melanoma Early Detection Study (MoleMed)

Melanoma Clinical Trial

— MoleMed  

Official title:

A Multicenter, Ambispective, Low-interventional Clinical Study Evaluating Molecular Genetic Markers for Non-invasive Differential Diagnosis of Benign and Malignant Pigmented Skin and Mucosal Neoplasms

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04353050
• Other study ID #: MoleMed-0320
• Status: Recruiting
• Phase: N/A
• Start date: April 1, 2020
• Est. completion date: November 1, 2023

Study information

• Verified date: June 2022
• Source: Russian Academy of Medical Sciences
• Contact: Igor V Samoylenko, MD, PhD
• Phone: ?+7 (909) 972-93-84?
• Email: i.samoylenko[@]ronc.ru
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a multicenter, ambispective, low-interventional clinical study evaluating molecular genetic markers for non-invasive differential diagnosis of benign and malignant pigmented skin and mucosal neoplasms. In retrospective cohorts genetics markers will be identified. In prospective cohort non-invasive adhesive system will be tested to identify malignant or benign lesions with prespecified sensitivity and specificity compared to other non-invasive techniques (i.e. dermoscopy) and using histopathological examination as a "golden standard".

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 350
• Est. completion date: November 1, 2023
• Est. primary completion date: January 1, 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

Cohort 1 (retrospective):

• Histologically confirmed diagnosis of melanocytic neoplasm of the skin or mucous membranes (benign, malignant or with unclear potential);

• The presence of a paraffin block with a tumor suitable for molecular genetic analysis;

• Signed informed consent form for living patients (for deceased, signing of a consent form with legal representatives is not required);

• Patient's age is over 18 years for the period of inclusion in the study (at the time of signing the consent form for living patients or for the excision biopsy period for deceased patients);

• Known clinical data of the patient (gender, age, skin phototype), hereditary history, medical history and follow-up of treatment outcomes for at least 5 years

2. Cohort 2 (retrospective):

• Histologically confirmed diagnosis of melanocytic neoplasm of the skin or mucous membranes (benign, malignant or with unclear potential);

• The presence of a paraffin block with a tumor suitable for molecular genetic analysis

• The presence of cytological preparations (at least 2 glasses) of the primary tumor with tumor material

• Signed informed consent form for living patients (for deceased, signing of a consent form with legal representatives is not required);

• Patient's age is over 18 years for the period of inclusion in the study (at the time of signing the consent form for living patients or for the excision biopsy period for deceased patients);

• A known medical history and follow-up of treatment outcomes for at least 6 months.

3. Cohort 3 (prospective):

• Clinically (including any type of dermatoscopy or other non-invasive diagnostic methods) suspected diagnosis of malignant melanocytic neoplasm (or neoplasms) of the skin or mucous membranes (or lesion(s) with unclear malignant potential)

• The patient is scheduled to undergo an excision biopsy (or wide excision) of the neoplasm (s) of the skin or mucous membranes within 3 months from the date of inclusion in the study and the patient is able to tolerate this intervention;

• Signed Informed Consent Form

Exclusion Criteria:

Cohort 1:

• Unknown histological diagnosis (no information on the melanocytic nature of the neoplasm)

• Unsuitable for analysis paraffin block with a tumor or its absence

• Unknown history or lack of traceability after diagnosis within 5 years

• For the period of inclusion in the study (signing an informed consent form for living patients or an excision biopsy for deceased patients), the patient's age is under 18 years

2. Cohort 2:

• Unknown histological diagnosis (no information on the melanocytic nature of the neoplasm)

• Unsuitable for analysis paraffin block with a tumor or its absence

• Unsuitable for analysis cytological preparations/smears (or the absence of tumor cells in cytological preparations)

• Unknown history or lack of traceability after diagnosis within 6 months.

• For the period of inclusion in the study (signing an informed consent form for living patients or an excision biopsy for deceased patients), the patient's age is under 18 years

3. Cohort 3 (prospective):

• The patient is NOT scheduled to undergo an excision biopsy (or wide excision) of the neoplasm (s) of the skin or mucous membranes in the next 3 months since inclusion in the study OR the patient is not able to tolerate this intervention;

• The available morphological or cytological confirmation of the nature of the neoplasm (s) (benign or malignant), which (s) is planned to be removed in the framework of this study,

• Ulcerated neoplasms;

• Contact bleeding neoplasms;

• Non-melanocytic neoplasms;

• Neoplasms with an area of more than 5 sq. cm

• Neoplasms located subcutaneously or in soft tissues and, according to clinical signs, not associated with the skin

• Known allergy to any component of the applied adhesive system;

• Inability of the patient to follow the study procedures (including contacting the researcher during the follow-up visits) or other reasons that, in the opinion of the principal investigator, may become an obstacle for the patient to participate in the study

Related Conditions & MeSH terms

• Dysplastic Nevus Syndrome
• Hyperplasia
• Melanoma
• Melanoma (Skin)
• Melanosis
• Moles
• Mucosal Melanoma
• Mucosal Melanosis
• Nevi, Dysplastic
• Nevi, Spindle Cell
• Nevus
• Nevus, Blue
• Nevus, Pigmented
• Nevus, Spitz

Intervention

Procedure:
• Non-invasive adhesive system (patch)
The already registered on the market adhesive skin patch will be applied and removed for several times on the pigmented skin (or mucosal) lesion just before the preplanned excisional biopsy after local anaesthesia have been already administered. Excisional biopsy and local anaesthesia are not the part of this study and will be carried out according to local practice

Locations

Country	Name	City	State
Russian Federation	N.N. Blokhin Russian Cancer Research Center	Moscow	??????
Russian Federation	Privolzhsky Research Medical University of the Ministry of Health of the Russian Federation	Nizhny Novgorod

Sponsors (2)

Lead Sponsor	Collaborator
Russian Academy of Medical Sciences	Blokhin's Russian Cancer Research Center

Country where clinical trial is conducted

Russian Federation, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Sensitivity and specificity on the investigated non-invasive genetic method for diffrential diagnosis of benign and malignant melanocytic lesions compared to histopathological examination	•Assessment of the sensitivity and specificity of a complex of molecular genetic studies applicable for non-invasive differential diagnosis of benign and malignant melanocytic neoplasms of the skin and mucous membranes in comparison with a standard histological examination	April 2020 - Nov 2022
Secondary	Sensitivity and specificity on the investigated non-invasive genetic method for diffrential diagnosis of benign and malignant melanocytic lesions compared to other non-invasive diagnostic tools (i.e. dermoscopy)	Assessment of the sensitivity, specificity, positive and negative prognostic significance of the developed molecular genetic method for non-invasive differential diagnosis of benign and malignant pigmented neoplasms of the skin and mucous membranes in comparison with clinical diagnosis with an naked eye by an oncologist or dermatologist	up to 12 months
Secondary	Describe some parameters of the identified malignant tumors		up to 12 months
Secondary	Describe the frequency of relapse (local, regional and systemic) within the observation period		up to 3 years